- /
- Supported exchanges /
- SHG /
- 688062.SHG
Mabwell (Shanghai) Bioscience Co. Ltd. A (688062 SHG) stock market data APIs
Mabwell (Shanghai) Bioscience Co. Ltd. A Financial Data Overview
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products in China and internationally. The company offers its products for oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection; MAILISHU for the treatment of postmenopausal women with osteoporosis; JUNMAIKANG, an immunological product; and MAIWEIJIAN for giant cell tumor of bone. The company's oncology products pipeline includes 9MW2821 which is in phase III clinical trial; 6MW3211, which is in phase II of clinical trial; 6MW3211 which is in phase II clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; and 8MW0511, which has completed phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; hematology product comprising 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is headquartered in Shanghai, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mabwell (Shanghai) Bioscience Co. Ltd. A data using free add-ons & libraries
Get Mabwell (Shanghai) Bioscience Co. Ltd. A Fundamental Data
Mabwell (Shanghai) Bioscience Co. Ltd. A Fundamental data includes:
- Net Revenue: 169 M
- EBITDA: -1 017 080 768
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-03-31
- EPS/Forecast: NaN
Get Mabwell (Shanghai) Bioscience Co. Ltd. A End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mabwell (Shanghai) Bioscience Co. Ltd. A News
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) o...
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) o...
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been...
FDA Grants Orphan Drug Designation to 7MW3711
SHANGHAI, July 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel B7-H3-targeting ADC (R...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.